Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era
Authors:
- 23 July 2023
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 98 (10) , 1619-1626
Abstract
Patients with chronic myeloid leukemia (CML) and T315I mutation generally have a poor prognosis. Their outcome in the post‐ponatinib era remains unclear. We reviewed patients with CML in chronic (CP) or accelerated phase (AP) who developed a T315I mutation between March 15, 2004, and July 26, 2022. Patients were divided into CP, AP, or blastic phase (BP) at the time of mutation detection. Overall survival (OS) was defined from the time of mutation detection to the date of death or last follow‐up. We identified a total of 107 patients: 54 (51%) in CP, 14 (13%) in AP, and 39 (36%) in BP. One hundred and two patients received subsequent therapy after the T315I mutation was detected. At a median follow‐up of 75 months (95% CI, 41–110), the median OS was 49 months (95% CI, 26–73) and the 5‐year OS rate was 44%. Patients who were in CML‐CP at the time of mutation detection had better survival compared with those in AP or BP, with a median OS of 132, 31, and 6 months, and 5‐year OS rates of 70%, 37%, and 10%, respectively (p < .001). Patients with CML‐CP treated with ponatinib and/or asciminib had a 5‐year OS of 77% compared with 50% in those who received other treatments (chemotherapy, second‐generation tyrosine kinase inhibitors, homoharringtonine, and investigational drugs) (p = .14). In summary, patients with CML‐CP at the time of T315I mutation detection may have a relatively indolent disease course with a long‐term OS of 70%. Treatment with third‐generation tyrosine kinase inhibitors seemed to improve survival in patients with CML‐CP.Keywords
Funding Information
- National Institutes of Health
This publication has 26 references indexed in Scilit:
- The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysisHaematologica, 2013
- Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceBlood, 2012
- Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutationBlood, 2009
- The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABLLeukemia, 2009
- Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitorsBlood, 2007
- Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylateLeukemia, 2006
- Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)Leukemia, 2006
- Staging of chronic myeloid leukemia in the imatinib eraCancer, 2006
- High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapyBlood, 2005
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003